Abstract
High-dose therapy with subsequent allogeneic or autologous transplantation of haemopoietic progenitor cells has proved to be an important therapy for patients with haematological malignancies, certain non-haematological cancers and several nonmalignant disorders such as severe aplastic anaemia. Allogeneic and autologous transplantation are associated with specific complications. One major problem after allotransplantation is the graft versus host disease with jaundice, diarrhoea and erythema. The major problem of autologous stem cell transplantation is a potential reinfusion of contaminating tumor cells. Allogeneic transplantation has been refined, and an approach to modulate graft versus host disease is a partial or complete lymphocyte depletion. Especially in the allogeneic setting, the field of cell therapy for modulation of graft versus host disease and treatment of transplant-related complications is expanding. For autologous transplantation different techniques to purge autografts from malignant contaminants have been developed. These cell selection techniques consist of immunological, biological, cultural, chemotherapeutical and physical techniques. This article reviews techniques currently used for graft engineering in bone marrow and blood stem cell transplantation.